

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Page **1** of **9** 

**Initial preparation date:** 16.10.2024

### Cosacthen 0.25 mg/ml solution for injection for dogs

#### **SECTION 1: Identification**

#### **Product identifier**

**Product name:** Cosacthen 0.25 mg/ml solution for injection for dogs

Synonyms: Cosyntropin; a1-24-corticotropin; ACTH1-24; Corticotrophin- (1-24)-tetracosapeptide;

Tetracosactide

#### Recommended use of the product and restriction on use:

**Relevant identified uses:** VETERINARY USE: For the evaluation of adrenal function in dogs.

Uses advised against: Not for human use.

Reasons why uses advised against: Veterinary product.

#### Manufacturer or supplier details

**Supplier:** 

### **Dechra Veterinary Products NZ Limited**

PO Box 1604,

Paraparaumu Beach, 5252

New Zealand

Phone: 0800 479 838 Email: info.nz@dechra.com

Website: http://www.dechra.co.nz/

#### **Emergency telephone number:**

**New Zealand** 

National Poisons Centre

0800 764 766

#### **SECTION 2: Hazards identification**

Not Classified as a Dangerous Good according to NZS 5433:2012 Transport of Dangerous Goods on Land.

Classified in accordance with the Hazardous Substances (Hazard Classification) Notice 2020.

**HSNO Classification or Subclasses – Physical hazards:** Not applicable

**HSNO Classification or Subclasses – Health hazards:** Not applicable

HSNO Classification or Subclasses – Environmental hazards: Not applicable

**GHS classification:** Not a hazardous substance or mixture.

Hazard pictogram(s): None

Signal word: None

Hazard statements: None

**Precautionary statements: None** 

Hazards not otherwise classified: None

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 2 of 9

### Cosacthen 0.25 mg/ml solution for injection for dogs

#### **SECTION 3: Composition/information on ingredients**

Identification	Name	Weight %
CAS number: 16960-16-0	Tetracosactide	0.025

#### Additional information:

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret under the provisions of sections 55 (7) of the HSNO Act.

### **SECTION 4: First-aid measures**

# For advice, contact a Poisons Information Center (e.g. phone Australia 131 126, New Zealand 0800 764 766) or a doctor.

#### **Description of first aid measures**

#### **General notes:**

Show this Safety Data Sheet to the doctor in attendance.

#### After inhalation:

If inhaled, remove person to fresh air and place in a position comfortable for breathing. If respiratory symptoms develop or persist, seek medical advice/attention.

#### After skin contact:

Wash affected area with plenty of soap and water. Remove contaminated clothing and launder before reuse. If skin irritation develops or persists, seek medical advice/attention.

#### After eye contact:

Immediately rinse eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 15 minutes. If eye irritation develops or persists, seek medical advice/attention.

### After swallowing:

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

#### Most important symptoms and effects, both acute and delayed:

#### **Acute symptoms and effects:**

No significant acute effects/symptoms.

#### **Delayed symptoms and effects:**

No significant delayed effects/symptoms.

### Immediate medical attention and special treatment

#### **Specific treatment:**

Not determined or not applicable.

#### Notes for the doctor:

Treat symptomatically.

### **Workplace Facilities:**

No additional information.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 3 of 9

#### Cosacthen 0.25 mg/ml solution for injection for dogs

#### **SECTION 5: Fire-fighting measures**

#### **Extinguishing media**

#### Suitable extinguishing media:

Water mist/fog, carbon dioxide, dry chemical or alcohol resistant foam.

#### **Unsuitable extinguishing media:**

Do not use water jet.

#### **Specific hazards during fire-fighting:**

Thermal decomposition may produce irritating/toxic fumes/gases.

#### **Special protective equipment for firefighters:**

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA).

#### **Special precautions:**

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts. Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers. Avoid unnecessary run-off of extinguishing media which may cause pollution.

### **Hazchem or Emergency Action Code:**

Not Applicable.

#### **SECTION 6: Accidental release measures**

#### Personal precautions, protective equipment and emergency procedures:

Evacuate unnecessary personnel. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Avoid contact with skin, eyes and clothing. Avoid breathing mist, vapor, dust, fume and spray. Do not walk through spilled material. Wash thoroughly after handling.

#### **Environmental precautions:**

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

#### Methods and material for containment and cleaning up:

Do not touch damaged containers or spilled material unless wearing appropriate personal protective clothing. Stop leak if you can do it without risk. Contain and collect spillage and place in suitable container for future disposal. Dispose of in accordance with all applicable regulations (see Section 13).

#### **Reference to other sections:**

For personal protective equipment see Section 8. For disposal see Section 13.

#### **SECTION 7: Handling and storage precautions**

#### **Precautions for safe handling:**

Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Avoid breathing mist/vapor/spray/dust. Do not eat, drink, smoke, or use personal products when handling chemical substances. Avoid contact with skin, eyes and clothing. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

#### Conditions for safe storage, including any incompatibilities:

Store in cool, dry, well-ventilated location out of direct sunlight. Keep away from food and beverages. Protect from freezing and physical damage. Store away from heat, open flames and other sources of ignition. Keep container tightly sealed. Store away from incompatible materials (See Section 10).

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 4 of 9

### Cosacthen 0.25 mg/ml solution for injection for dogs

Storage temperature: 2 °C – 8 °C (refrigerate, do not freeze).

Container type: Carton containing Type I clear glass vial with a coated rubber stopper and aluminium seal).

### Safe packaging material

#### Suitable material:

Not determined or not applicable.

#### **Unsuitable material:**

Not determined or not applicable.

#### **SECTION 8: Exposure controls and personal protection**

Only those substances with limit values have been included below.

### **Occupational Exposure limit values:**

No occupational exposure limits noted for the ingredient(s).

### **Biological limit value:**

No biological exposure limits noted for the ingredient(s).

### Information on monitoring procedures:

Not determined or not applicable

### **Appropriate engineering controls:**

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

#### **Personal protection equipment**

#### **Eye and face protection:**

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

#### Skin and body protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

#### **Respiratory protection:**

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

#### **General hygienic measures:**

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 5 of 9

### Cosacthen 0.25 mg/ml solution for injection for dogs

### **SECTION 9: Physical and chemical properties**

Physical state	Liquid
Odour	Not determined or not available.
Odour threshold	Not determined or not available.
рН	3.8 - 4.5
Melting point/freezing point	Not determined or not available.
Initial boiling point/range	100°C (212°F)
Flash point (closed cup)	In water – no flash point
Flammability (solid, gas)	Not determined or not available.
Upper flammability/explosive limit	Not determined or not available.
Lower flammability/explosive limit	Not determined or not available.
Vapour pressure	Not determined or not available.
Vapour density	Not determined or not available.
Relative density	Not determined or not available.
Solubilities	Miscible in water
Partition coefficient (n-octanol/water)	Not determined or not available.
Auto/Self-ignition temperature	Not determined or not available.
Decomposition temperature	Not determined or not available.
Kinematic viscosity	Not determined or not available.
Particle characteristics	Not determined or not available.

#### Other information:

Density	1.004 g/ml
Molecular weight	2933

### **SECTION 10: Stability and reactivity**

### Reactivity:

Not reactive under recommended handling and storage conditions.

#### **Chemical stability:**

Stable under recommended handling and storage conditions.

#### **Possibility of hazardous reactions:**

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

#### Conditions to avoid:

Extreme heat, open flames, hot surfaces, sparks, ignition sources and incompatible materials.

#### **Incompatible materials:**

None known.

### **Hazardous decomposition products:**

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 6 of 9

### Cosacthen 0.25 mg/ml solution for injection for dogs

#### **SECTION 11: Toxicological information**

#### **Acute toxicity:**

**Assessment:** Based on available data, the classification criteria are not met.

Product data: No data available.

#### Substance data:

Name	Route	Result
Tetracosactide	Inhalation ATE	LC50 Rat: 1.5 mg/L (4 hr [dust/mist])

#### Skin corrosion/irritation

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

Substance data: No data available.

Serious eye damage/irritation

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

Respiratory or skin sensitization:

**Assessment:** Based on available data, the classification criteria are not met.

Product data: No data available.

#### Substance data:

Name	Result	
Tetracosactide	May cause an allergic skin reaction.	
	May cause allergy or asthma symptoms or breathing difficulties if inhaled.	

#### Carcinogenicity

Assessment: Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

International Agency for Research on Cancer (IARC): None of the ingredients are listed.

### Germ cell mutagenicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available

#### Reproductive toxicity

Assessment: Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

## Specific target organ toxicity (single exposure)

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.10.2024 Page **7** of **9** 

### Cosacthen 0.25 mg/ml solution for injection for dogs

#### Specific target organ toxicity (repeated exposure)

Assessment: Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

#### **Aspiration toxicity**

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

#### Information on likely routes of exposure:

Inhalation; ingestion; skin contact; eye contact

### Symptoms related to the physical, chemical and toxicological characteristics:

See section 4 of this SDS.

#### Other information:

No additional information.

#### **SECTION 12: Ecological information**

#### **Acute (short-term) toxicity**

Assessment: Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

### Chronic (long-term) toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:** No data available. **Substance data:** No data available.

# Persistence and degradability

**Product data:** No data available. **Substance data:** No data available.

#### **Bioaccumulative potential**

**Product data:** No data available. **Substance data:** No data available.

### Mobility in soil

**Product data:** No data available. **Substance data:** No data available.

#### Hazard to the ozone layer

Product data: No data available.

Substance data: No data available.

Other adverse effects: No additional information.

#### **SECTION 13: Disposal considerations**

### **Disposal methods:**

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory agencies. Dispose of in accordance with all applicable local, regional, state and federal regulations.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

**Initial preparation date:** 16.10.2024 Page **8** of **9** 

### Cosacthen 0.25 mg/ml solution for injection for dogs

#### **Contaminated packages:**

Not determined or not applicable.

### Disposal methods that should not be used:

No additional information.

### **SECTION 14: Transportation information**

### Road/Rail transport: (NZS 5433:1999)

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

### **International Air Transport Association Dangerous Goods Regulations (IATA-ICAO)**

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

### **International Maritime Dangerous Goods (IMDG)**

UN number	Not regulated
UN proper shipping name	Not regulated
UN transport hazard class(es)	None
Packing group	None
Environmental hazards	None
Special precautions for user	None

### Transport in bulk according to Annex II of MARPOL and the IBC Code:

Bulk Name	None
	HOLIC
Ship type	None
Pollution category	None

### **SECTION 15: Regulatory information**

#### **New Zealand Inventory of Chemicals (NZIoC):**

Tetracosactide	16960-16-0	Not Listed
----------------	------------	------------

**HSNO Classification or Subclasses:** Not Applicable.

According to New Zealand, Hazardous Substances and New Organisms Act 1996 (HSNO Act) and Regulations, as amended.

Initial preparation date: 16.10.2024 Page 9 of 9

### Cosacthen 0.25 mg/ml solution for injection for dogs

HSNO Group Standard Name:	HSNO Approval Number:
Veterinary Medicines (Limited Pack Size,	HSR100757
Finished Dose) Group Standard 2020	

**HSNO Controls:** Not determined.

**Approved handler test certificate:** Not determined.

Tracking: Not determined.

**Controlled substance license requirements:** Not applicable. **Agricultural Compounds and Veterinary Medicines Act 1997:** 

ACVM number A011944

Montreal Protocol (Ozone Depleting Substances): None of the ingredients are listed.

Stockholm Convention (Persistent Organic Pollutants): None of the ingredients are listed.

Rotterdam Convention (Prior Informed Consent): None of the ingredients are listed.

Basel Convention (Hazardous Waste): None of the ingredients are listed.

#### SECTION 16: Other information

#### **Abbreviations and Acronyms:**

ATE	Acute Toxicity Estimate	
BCF	Bioconcentration Factor	
CAS	Chemical Abstracts Service	
EC50	Effective Concentration of 50%	
GHS	Globally Harmonized System	
HSNO	Hazardous Substances and New Organisms	
IARC	International Agency for Research on Cancer	
IATA	International Air Transport Association	
IBC	Intermediate Bulk Container	
ICAO	International Civil Aviation Organization	
IMDG	International Maritime Dangerous Goods	
LC50	Lethal Concentration 50%	
LD50	Lethal Dose 50%	
MARPOL	International Convention for the Prevention of Pollution from Ships	
NZIoC	New Zealand Inventory of Chemicals	
TWA	Time Weighted Average	
UN	United Nations	
VOC	Volatile Organic Compounds	

### **Disclaimer:**

The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

**Initial preparation date: 16.10.2024**